Mr. Alan Moore:

This goes back to the initial purpose of the protocol. Deputy O'Callaghan raised good points on how providers will ensure that users act on their obligations. When the legal framework is in place and the protocol is ratified there will be awareness of it. Users in Ireland would be in the sectors the Minister of State mentioned, including pharmaceuticals, cosmetics, research and any institution that is dealing with organic genetic material. The provider countries are where it starts. If the genetic material is from Peru and it is a plant-based material used in cosmetics or has a medical use, the providers of the resource will agree terms with the user. This is where it starts. This goes into the online ABS clearinghouse. There will be online documentation that we will all sign up to once the protocol is ratified. This is where the obligations will be monitored through due diligence declarations made by the user that match the documents lodged by the provider countries. The clearinghouse will be brought into force by the protocol to ensure the obligations are met. The legislation we have in place is to ensure we meet our obligations under the protocol and the EU ABS regulation. There will be no need for further legislation.